Trogocytosis-Mediated CLDN18.2 Acquisition by CD8+ T Cells Impairs Anti-Tumor Immunity and Drives Pancreatic Cancer Progression
This study reveals that CLDN18.2 acquired by CD8+ T cells through trogocytosis impairs their glucose metabolism and cytotoxic function, promoting pancreatic cancer progression and systemic immune senescence. Targeting this axis may enhance immunotherapy efficacy in PDAC.